Oncological Treatment Adverse Reaction Prediction: Development and Initial Validation of a Pharmacogenetic Model in Non-Small-Cell Lung Cancer Patients
Genes · 2025
DOI: 10.3390/genes16030265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Concetta Cafiero und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, SG Moscati Hospital, 74010 Statte, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: by Fondazione Roche per I Pazienti, Bando 2020 "Accanto a chi si prende cura"., Fondazione Roche per I Pazienti, Bando 2020 “Accanto a chi si prende cura”..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: The accurate prediction of adverse drug reactions (ADRs) to oncological treatments still poses a clinical challenge. Chemotherapy is usually selected based on clinical trials that do not consider patient variability in ADR risk. Consequently, many patients undergo multiple treatments to find the appropriate medication or dosage, enhancing ADR risks and increasing the chance of discontinuing therapy. We first aimed to develop a pharmacogenetic model for predicting chemotherapy-induced ADRs in cancer patients (the ANTIBLASTIC DRUG MULTIPANEL PLATFORM) and then to assess its feasibility and validate this model in patients with non-small-cell lung cancer (NSCLC) undergoing oncological treatments.
Methods
Seventy NSCLC patients of all stages that needed oncological treatment at our facility were enrolled, reflecting the typical population served by our institution, based on geographic and demographic characteristics. Treatments followed existing guidelines, and patients were continuously monitored for adverse reactions. We developed and used a multipanel platform based on 326 SNPs that we identified as strongly associated with response to cancer treatments. Subsequently, a network-based algorithm to link these SNPs to molecular and biological functions, as well as efficacy and adverse reactions to oncological treatments, was used.
Results
Data and blood samples were collected from 70 NSCLC patients. A bioinformatic analysis of all identified SNPs highlighted five clusters of patients based on variant aggregations and the associated genes, suggesting potential susceptibility to treatment-related toxicity. We assessed the feasibility of the platform and technically validated it by comparing NSCLC patients undergoing the same course of treatment with or without ADRs against the cluster combination. An odds ratio analysis confirmed the correlation between cluster allocation and increased ADR risk, indicating specific treatment susceptibilities.
Conclusions
The ANTIBLASTIC DRUG MULTIPANEL PLATFORM was easily applicable and able to predict ADRs in NSCLC patients undergoing oncological treatments. The application of this novel predictive model could significantly reduce adverse drug reactions and improve the rate of chemotherapy completion, enhancing patient outcomes and quality of life. Its potential for broader prescription management suggests significant treatment improvements in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, SG Moscati Hospital, 74010 Statte, Italy.
- Anatomic Pathology Unit, Fabrizio Spaziani Hospital, 03100 Frosinone, Italy.
- Interdisciplinary Department of Medicine, School of Medicine, University of Bari "Aldo Moro", 70124 Bari, Italy.
- Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Department of Biology College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
- Gynecology and Obstetrics Unit, Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.
- Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Sciences, IRCCS-Fondazione Bietti, 00184 Rome, Italy.
ORCID-Profile: Concetta Cafiero, Raffaele Palmirotta, Canio Martinelli, Luciano Giacò, Federica Persiani, Andrea Morrione, Antonio Giordano
Förderung
- by Fondazione Roche per I Pazienti, Bando 2020 "Accanto a chi si prende cura".
- Fondazione Roche per I Pazienti, Bando 2020 “Accanto a chi si prende cura”.
Zitieren
APA
Cafiero, C., Palmirotta, R., Martinelli, C., Micera, A., Giacò, L., Persiani, F., Morrione, A., Pastore, C., Nisi, C., Modoni, G., Galeano, T., Guarino, T., Foggetti, I., Nisticò, C., Giordano, A., & Pisconti, S. (2025). Oncological Treatment Adverse Reaction Prediction: Development and Initial Validation of a Pharmacogenetic Model in Non-Small-Cell Lung Cancer Patients. Genes. https://doi.org/10.3390/genes16030265
Vancouver
Cafiero C, Palmirotta R, Martinelli C, Micera A, Giacò L, Persiani F, et al. Oncological Treatment Adverse Reaction Prediction: Development and Initial Validation of a Pharmacogenetic Model in Non-Small-Cell Lung Cancer Patients. Genes. 2025. doi:10.3390/genes16030265
BibTeX
@article{Cafiero2025,
author = {Cafiero, Concetta and Palmirotta, Raffaele and Martinelli, Canio and Micera, Alessandra and Giacò, Luciano and Persiani, Federica and Morrione, Andrea and Pastore, Cosimo and Nisi, Claudia and Modoni, Gabriella and Galeano, Teresa and Guarino, Tiziana and Foggetti, Ilaria and Nisticò, Cecilia and Giordano, Antonio and Pisconti, Salvatore},
title = {Oncological Treatment Adverse Reaction Prediction: Development and Initial Validation of a Pharmacogenetic Model in Non-Small-Cell Lung Cancer Patients},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16030265}
}
EUVIMED